La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Suven Pharmaceuticals Gestione
Gestione criteri di controllo 0/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Sudhir Singh
Amministratore delegato
n/a
Compenso totale
| Percentuale dello stipendio del CEO | n/a |
| Mandato del CEO | less than a year |
| Proprietà del CEO | n/a |
| Durata media del management | less than a year |
| Durata media del Consiglio di amministrazione | less than a year |
Aggiornamenti recenti sulla gestione
Recent updates
These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely
Dec 15
Robust Earnings May Not Tell The Whole Story For Suven Pharmaceuticals (NSE:SUVENPHAR)
Aug 03Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?
May 12Suven Pharmaceuticals Limited (NSE:SUVENPHAR) Investors Are Less Pessimistic Than Expected
Mar 26Here's Why We Think Suven Pharmaceuticals (NSE:SUVENPHAR) Is Well Worth Watching
Mar 07These 4 Measures Indicate That Suven Pharmaceuticals (NSE:SUVENPHAR) Is Using Debt Safely
Nov 30Do Suven Pharmaceuticals's (NSE:SUVENPHAR) Earnings Warrant Your Attention?
Sep 03Here's Why Suven Pharmaceuticals (NSE:SUVENPHAR) Can Manage Its Debt Responsibly
Aug 04Analysts Have Made A Financial Statement On Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) Full-Year Report
Jun 11With EPS Growth And More, Suven Pharmaceuticals (NSE:SUVENPHAR) Is Interesting
Apr 13Does Suven Pharmaceuticals (NSE:SUVENPHAR) Have A Healthy Balance Sheet?
Mar 08Can Suven Pharmaceuticals Limited's (NSE:SUVENPHAR) ROE Continue To Surpass The Industry Average?
Feb 08AMMINISTRATORE DELEGATO
Sudhir Singh (59 yo)
less than a year
Mandato
Dr. Sudhir Kumar Singh, Ph.D. serves as Chief Executive Officer since September 29, 2023 at Suven Pharmaceuticals Ltd. He served as Chief Operating Officer of Aragen Life Sciences Private Limited from Sept...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman | less than a year | ₹27.27m | Nessun dato | |
| Chief Executive Officer | less than a year | Nessun dato | Nessun dato | |
| Chief Financial Officer | less than a year | Nessun dato | Nessun dato | |
| Head of Investor Relations | no data | Nessun dato | Nessun dato | |
| Chief Quality & Compliance Officer | no data | Nessun dato | Nessun dato | |
| Chief Human Resources Officer | less than a year | Nessun dato | Nessun dato | |
| MD & Director | no data | Nessun dato | Nessun dato | |
| Chief Strategy Officer | less than a year | Nessun dato | Nessun dato | |
| Chief Commercial Officer | less than a year | Nessun dato | Nessun dato | |
| Vice President of Corporate Affairs | 3.6yrs | Nessun dato | Nessun dato |
0.9yrs
Durata media
54yo
Età media
Gestione esperta: Il team dirigenziale di SUVENPHAR non è considerato esperto (durata media 0.9 anni), il che suggerisce un nuovo team.
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Executive Chairman | less than a year | ₹27.27m | Nessun dato | |
| MD & Director | less than a year | Nessun dato | Nessun dato | |
| Member of Advisory Council | less than a year | Nessun dato | Nessun dato | |
| Member of Advisory Council | less than a year | ₹68.35m | 0.00079% ₹ 2.1m | |
| Non-Executive Director | less than a year | Nessun dato | Nessun dato | |
| Non-Executive Director | less than a year | Nessun dato | Nessun dato | |
| Independent Director | less than a year | ₹1.36m | Nessun dato | |
| Independent Director | less than a year | ₹1.36m | Nessun dato | |
| Member of Advisory Council | less than a year | Nessun dato | Nessun dato | |
| Independent Director | less than a year | ₹1.07m | Nessun dato | |
| Independent Director | less than a year | ₹1.36m | Nessun dato |
0.9yrs
Durata media
62yo
Età media
Consiglio di amministrazione esperto: Il consiglio di amministrazione di SUVENPHAR non è considerato esperto (durata media del mandato 0.9 anni), il che suggerisce un nuovo consiglio.